Lincoln Pharmaceuticals Ltd Reports Standalone Net Profit of Rs. 27.70 crore in Q1 FY26, growth of 16.93% Y-o-Y

Financial Highlights (Standalone)

(Amount in Cr except EPS)

Ahmedabad, August 07, 2025: Lincoln Pharmaceuticals Ltd (BSE: 531633, NSE: LINCOLN), one of India’s leading healthcare companies has reported its operational and financial performance for Q1 FY 2025-26 ended 30th June 2025. Company has reported a standalone net profit of Rs. 27.70 crore for the Q1 FY 2025-26 as compared to the net profit of Rs. 23.69 crore reported in Q1 FY 2024-25, growth of 16.93% Y-o-Y. Total income for the quarter ended June 2025 was reported at Rs. 169.34 crore, higher by 7.39% Y-o-Y over total income of Rs. 157.69 crore in Q1 FY2024-25. EBITDA for Q1 FY26 was reported at Rs. 39.08 crore as compared to EBITDA of Rs. 33.14 crore in Q1 FY25, growth of 17.92% Y-o-Y. EPS for Q1 FY26 was at Rs. 13.82 per share. 

Share price of the company rise over 10% post results to intraday high of Rs. 598.40 per share on NSE from previous close of Rs. 531.15 per share. 

Company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.95% in June 2024 to 5.13% as of June 2025. 

Speaking on the financial performance and future plans, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said

·         Many countries had been added for the Cephalosporin plant products and product registration for these countries will start soon.

·         During the Q1 FY26 company had started Bulk Drug Manufacturing Plant. For which product approval had been received for 10 products and others are under process. Company invested Rs. 4 Cr for this plant from internal accruals of the company. 

The company’s growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women’s healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company’s liquidity remains solid. 

Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2–3 years. With recent entry into the Canadian market and approvals from TGA – Australia and EU GMP, the company is poised for further global expansion. 

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.

Corporate Comm India (CCI Newswire)